Unusual Transmission of *Plasmodium falciparum*, Bordeaux, France, 2009

Marc-Olivier Vareil, Olivier Tandonnet, Audrey Chemoul, Hervé Bogreau, Mélanie Saint-Léger, Maguy Micheau, Pascal Millet, Jean-Louis Koeck, Alexandre Boyer, Christophe Rogier, and Denis Malvy

*Plasmodium falciparum* malaria is usually transmitted by mosquitoes. We report 2 cases in France transmitted by other modes: occupational blood exposure and blood transfusion. Even where malaria is not endemic, it should be considered as a cause of unexplained acute fever.

Unusual forms of parasitic infection, such as those acquired by blood transfusion (1,2) or accidental exposure to infected blood (3), may be challenging to diagnose in areas where these infections are not endemic (4). We report 2 cases of *Plasmodium falciparum* malaria transmitted by routes other than mosquito vectors: occupational blood exposure and blood transfusion.

The Patients

Patient 1, a 36-year-old woman who worked as a technician in a clinical laboratory, was admitted to Bordeaux Hospital, France, on June 2, 2009. She had a 7-day history of high fever (up to 39.5°C), rigors, headache, and jaundice. Hematologic tests showed decreased platelets (33,000 x 10⁹ platelets/L) and increased serum C-reactive protein (130 mg/L; reference <5 mg/L). Although the patient denied having traveled abroad in the past 5 years, she lived near an international airport, and her clinical signs were typical of malaria. Consequently, thick and thin blood smears were performed and indicated *P. falciparum* parasitemia of 0.1%. Serum bilirubin was 86 µmol/L (reference 3–18 µmol/L). By 6 hours after hospital admission, her condition had dramatically worsened, with hemodynamic collapse (blood pressure 60/32 mm Hg) associated with macroscopic hemoglobinuria; parasitemia increased to 6%. All viral and bacteriologic testing results were negative. Treatment was intravenous quinine for 8.3 mg/kg, followed by maintenance dose of 8.3 mg/kg 3×/d). After 5 days, her medication was switched to oral quinine for another 2 days. Parasitemia was absent 6 days after starting quinine, and the patient was discharged 2 days later. Blood smears were negative 21 days after discharge.

Patient 1 later recalled that 2 weeks before hospital admission she had been injured by a broken, blood-contaminated, malaria diagnostic (QBC) test tube at work. Because she considered the incident trivial, she did not inform her workplace of it. Had she done so, the standard blood exposure protocol would have been automatically triggered. The source of the blood was subsequently traced to a patient returning from the Congo, for whom *P. falciparum* parasitemia of 4% had been diagnosed when the blood sample was taken. Genotyping of blood samples from patient 1 and the presumed source traveler were performed. *P. falciparum* isolates were genotyped at the 7A11, C4M79, PI2802, and PI2689 microsatellite loci and at the highly polymorphic loci of the merozoite surface protein 1 and 2 antigen genes by fluorescent end-labeled nested PCR and restriction fragment length polymorphism analysis (5–7). Results showed that the 2 infections had the same molecular signature and complete homology and were confirmed by genotypic analysis of resistance markers. A threonine variant on codon K76T point mutation of *P. falciparum* chloroquine resistance transporter and an identical level of resistance to antifolate drugs (*P. falciparum* dihydrofolate reductase–thymidylate synthase point mutations at positions 51, 59, and 108) were found (Table) (5,7). A diagnosis of severe malaria as a result of occupational percutaneous blood exposure was therefore retained.

Patient 2 was a 15-day-old girl who was referred from Dakar, Senegal, where she had been born on March 11, 2009. She was the third child of a Lebanese family who had no known genetic illness and who lived in an air-conditioned house. The pregnancy had been uneventful, and the infant was delivered at term. Her blood group was B Rh+. At day 14 after birth, pallor and jaundice suggested severe neonatal anemia. Blood testing indicated decreased hemoglobinemia (5.2 g/dL; reference 9–14 g/dL) and reticulocytosis (260,000 x 10⁶ cells/L; reference 25,000–85,000 x 10⁶ cells/L). Serum C-reactive protein was <5 mg/L. The patient received a 60-mL whole blood transfusion from a
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 2, February 2011

Unusual Transmission of Plasmodium falciparum

Table. Genotyping results for 2 Plasmodium falciparum isolates, France, 2009

<table>
<thead>
<tr>
<th>Locus</th>
<th>Secondary case Type</th>
<th>Allele</th>
<th>Index case Type</th>
<th>Allele</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsatellites†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7A11</td>
<td>NA</td>
<td>119 bp</td>
<td>NA</td>
<td>119 bp</td>
</tr>
<tr>
<td>C4M79</td>
<td>NA</td>
<td>203 bp</td>
<td>NA</td>
<td>203 bp</td>
</tr>
<tr>
<td>P12802</td>
<td>NA</td>
<td>139 bp</td>
<td>NA</td>
<td>139 bp</td>
</tr>
<tr>
<td>P12689</td>
<td>NA</td>
<td>87 bp</td>
<td>NA</td>
<td>87 bp</td>
</tr>
<tr>
<td>Antigen genes‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>msp-1</td>
<td>Ro33</td>
<td>149 bp</td>
<td>Ro33</td>
<td>149 bp</td>
</tr>
<tr>
<td>msp-2</td>
<td>FC27</td>
<td>413 bp</td>
<td>FC27</td>
<td>413 bp</td>
</tr>
<tr>
<td>Drug resistance genes§</td>
<td>pfcrt codon 76</td>
<td>Mutated</td>
<td>ACA</td>
<td>Mutated</td>
</tr>
<tr>
<td>Codon 16</td>
<td>Wild-type</td>
<td>GCA</td>
<td>Wild-type</td>
<td>GCA</td>
</tr>
<tr>
<td>Codon 51</td>
<td>Mutated</td>
<td>ATT</td>
<td>Mutated</td>
<td>ATT</td>
</tr>
<tr>
<td>Codon 59</td>
<td>Mutated</td>
<td>CGT</td>
<td>Mutated</td>
<td>CGT</td>
</tr>
<tr>
<td>Codon 108</td>
<td>Mutated</td>
<td>AAC</td>
<td>Mutated</td>
<td>AAC</td>
</tr>
<tr>
<td>Codon 164</td>
<td>Wild-type</td>
<td>ÁTA</td>
<td>Wild-type</td>
<td>ÁTA</td>
</tr>
</tbody>
</table>
| *NA, not applicable; msp, merozoite surface protein; pfcrt, P. falciparum chloroquine resistance transporter; pfdhfr, P. falciparum dihydrofolate reductase.†Size of amplified DNA fragment expressed.‡Allelic family and size of amplified DNA fragment expressed.§Single-nucleotide polymorphism, mfcrt codon 76 point mutation was genotyped by nested PCR and restriction fragment-length polymorphism analysis. pfdhfr point mutations at positions 16, 51, 59, 108, and 164 were genotyped by nested PCR and primer expansion. Underlining indicates nucleotide positions that can be mutated.

compatible donor in Dakar on March 26; the next day, she was transferred to Bordeaux Hospital.

At the time of admission, hematologic testing confirmed severe regenerative hemolytic anemia (hemoglobin 9.5 g/dL, reticulocytes 320,000 × 10⁶ cells/L, and serum haptoglobin <0.08 g/L [reference 0.80–2.15 g/L]). Abdominal and transfontanellar echography showed no abnormalities. PCR specific for parvovirus B19 and cytomegalovirus was negative. Serologic testing for malaria, thick and thin blood smear, and specific PCR for P. falciparum pBRK1–14 in the newborn and her mother was negative. Investigation for ABO blood incompatibility or immunologically related hemolysis produced negative results. Screening of both parents and the newborn for inherited hemolysis excluded an erythrocyte membrane abnormality. Hemoglobinopathy and erythrocyte enzyme (glucose 6-phosphate dehydrogenase, pyruvate kinase, and hexokinase) deficiencies were also ruled out. The newborn and her parents were followed up weekly; no pertinent clinical findings or abnormal PCR and blood smear were found until 7 weeks after birth, when febrile thrombocytopenia (92,000 × 10⁹ platelets/L) and neutropenia (540 × 10⁹ cells/L) were detected.

At 7 weeks after birth, blood smears indicated P. falciparum parasitemia of 6%. Treatment with intravenous quinine formate at 8.3 mg/kg 3×/d for 4 days, followed by oral mefloquine (20 mg/kg) for 1 day led to prompt improvement. Follow-up at 3 and 5 months of age showed resolution of anemia and no relapse of malaria. Test results for hemolysis remained negative, and glucose 6-phosphate dehydrogenase and erythrocyte pyruvate kinase levels 6 months after transfusion were within normal limits. Although it could not be confirmed, neonatal anemia was attributed to fetal–maternal hemorrhage.

We contacted the clinic in Dakar, where the blood sample but not the donor could be traced. However, a thick and thin blood smear examination subsequently performed in Dakar was positive for P. falciparum, clearly supporting a diagnosis of transfusion-transmitted malaria.

Conclusions

In non–malaria-endemic countries, accidental blood-borne inoculation of P. falciparum after direct occupational exposure of health care or laboratory personnel has been rarely reported (8–10). The course of such occupationally acquired malaria may be critical if the inoculating injury is neglected or unrecognized, as it was by patient 1. This case emphasizes the need for laboratories handling blood to ensure that every accidental injury, however trivial it may seem, is declared and managed. As occurred with patient 1, a delayed diagnosis may also delay delivery of appropriate care for preventing severe or complicated illness (9,10).

Whereas most non–malaria-endemic countries, including France, are implementing selective screening strategies for blood product donors (11), prevention of transfusion-transmitted malaria in endemic areas such as Senegal remains a challenge because such screening is not routinely performed. For patients such as patient 2, malaria is rarely diagnosed in non–malaria-endemic countries (12,13). For this patient, the chronology of events and exposure to blood from a contaminated donor are highly suggestive of transfusion-transmitted malaria. In the absence of immunologic indicators that the mother had been exposed to P. falciparum, vertical transmission is extremely unlikely, and the risk for mosquito transmission is low because of the family’s living environment and the time of year. Nevertheless, without gene sequencing of parasites from the donor, transfusion-transmitted malaria cannot be demonstrated unequivocally.

Neonates are assumed to be able to counteract natural infection with malaria because of the predominance of fetal hemoglobin, which is not suitable for complete erythrocyte schizogony of P. falciparum (14). For patient 2, transfusion with infected adult blood may have compromised this capacity, enabling the infection to follow its natural course. In Senegal, blood transfusion recipients are routinely given antimalaria treatment (15). Unfortunately, such treatment cannot be extended to neonates because of lack of a validated and convenient therapeutic antimalaria regimen for this age group.

The above-mentioned types of malaria transmission are unusual. However, in non–malaria-endemic countries,
a recent history of blood transfusion or an episode of accidental inoculation of blood may account for malaria infection in persons who are not otherwise at risk.

Dr Vareil is a junior physician who specializes in internal medicine, intensive care medicine, and infectious and tropical diseases in the Tropical Medicine Division of the University Hospital Centre, Bordeaux, France. His main research interests are tropical medicine and care of patients with imported diseases, especially critical care.

References


Address for correspondence: Denis Malvy, Travel Clinics and Division of Tropical Medicine and Imported Diseases, Department of Internal Medicine and Tropical Diseases, Pôle Médecine-Urgences, Hôpital St-André, CHU, 1 Rue Jean-Burguet, 33075 Bordeaux Cedex, France; email: denis.malvy@chu-bordeaux.fr

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.